Navigation Links
Can Hormone Help Treat Multiple Sclerosis Long-Term?
Date:3/10/2013

SAN DIEGO, March 10, 2013 /PRNewswire-USNewswire/ -- A new study suggests that treatment with adrenocorticotropic hormone (ACTH) may be helpful for people whose multiple sclerosis (MS) is not well-controlled through their regular treatment. The study was released today and will be presented at the American Academy of Neurology's 65th Annual Meeting in San Diego, March 16 to 23, 2013.

The study involved 23 people with MS who were taking beta-interferon treatment and had at least one relapse or brain scan showing new disease activity within the previous year. They were considered to have "breakthrough" MS, which means that their treatment that had been working previously stopped being effective, leading to worsening disability and more frequent relapses, as well as increased evidence of disease activity on brain scans.

The study participants were given either ACTH or methylprednisolone as pulse therapy monthly in addition to their regular treatment for one year. The people with MS knew which treatment they were receiving, but the researchers examining them did not.

The participants were tested every three months for 15 months. Over that time, those receiving ACTH had fewer relapses, or 0.08 cumulative relapses per patient compared to 0.8 relapses per patient for those receiving methylprednisolone. Those taking ACTH also had no cases of psychiatric side effects, while those taking methylprednisolone had a cumulative number of 0.55 psychiatric episodes per patient.

"These results are of interest because few treatments are available for people with breakthrough MS," said study author Regina Berkovich , MD, PhD, of Keck Medical Center of USC in Los Angeles. "Further studies, including randomized controlled trials, are needed to validate these preliminary findings, but the results suggest a potential benefit of ACTH pulse therapy in breakthrough MS."

While ACTH has been approved for use in MS relapses for many years, its cost has limited its use to only those patients who are in need of a relapse treatment alternative to corticosteroids. This is believed to be the first study to have been done on its use as a chronic treatment for MS. ACTH is not FDA-approved for use as chronic treatment for MS.

The study was supported by a research grant from Questcor Pharmaceuticals, Inc., maker of ACTH.

Learn more about multiple sclerosis at http://www.aan.com/patients.

The American Academy of Neurology, an association of more than 25,000 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer's disease, stroke, migraine, multiple sclerosis, brain injury, Parkinson's disease and epilepsy.

For more information about the American Academy of Neurology, visit http://www.aan.com or find us on Facebook, Twitter, Google+ and YouTube.


'/>"/>
SOURCE American Academy of Neurology
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Product Differentiation to Boost European Human Growth Hormones Market, Says Frost & Sullivan
2. Transdermal Hormone Replacement: Products, Players, Markets and Forecasts
3. Endocrinology Market to 2018 - Advanced Injection Devices for Growth Hormone and Somatostatin will Improve Ease of Use for Patients
4. Early Detection of MS Treatment Complication May Improve Survival
5. Abattis Participates In Project On A Whole Plant Therapeutic For Treating Malaria And Other Diseases And Reducing Drug Resistance
6. Study: Surefire Medicals Technology Improves Delivery Of Embolics In Cancer Treatment
7. 95% Cure Rate for Prostate Cancer In Men Treated With HIFU (High Intensity Focused Ultrasound)
8. Boehringer Ingelheim Announces Interim Results Evaluating Virologic Response Rates in HCV/HIV Co-Infected Patients Treated with Faldaprevir
9. NeuroDerm Announces Positive Results of a Phase I Study of ND0612 for the Treatment of Parkinsons Disease
10. Bloomberg BNA Publishes Sixth Edition of False Claims Act Treatise
11. Studies Published in Pain Medicine Demonstrate Effectiveness of Minimally-Invasive Cooled Radiofrequency Treatment for Low Back Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... March 23, 2017  Drug diversion is a ... and deadly overdoses. A new oral fluid monitoring ... www.cordantsolutions.com , reports more detailed and actionable information ... potentially improve therapy adherence, patient safety, and help ... Comprehensive Oral fluid Rx Evaluation (CORE) system is ...
(Date:3/23/2017)... 23, 2017 Ascendis Pharma A/S (Nasdaq: ASND), ... to address significant unmet medical needs in rare diseases, ... call and webcast on Monday, April 3 during ENDO ... Orlando, Florida , to discuss new ... Growth Hormone, TransCon PTH and TransCon CNP). ...
(Date:3/23/2017)... , March 23, 2017  A new genetic ... accurate identification of individuals who carry HLA-B*15:02 ... a rare yet potentially deadly side effect of ... disorder.  The gene HLA-B*15:02 is strongly ... as Stevens-Johnson syndrome and toxic epidermal necrolysis in ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... 23, 2017 , ... PAINWeekEnd (PWE) Oklahoma City, on April ... will be an educational and exciting program providing busy clinicians and allied healthcare ... pain. , Oklahoma is in a healthcare crisis. The state ranks 46th in ...
(Date:3/23/2017)... New York, NY (PRWEB) , ... March 23, 2017 , ... 82% of adults are ... every 3 kids do not brush their teeth the minimum two times a day that ... teeth; with students missing 51 million hours of school and adults missing 164 million hours ...
(Date:3/23/2017)... ... March 23, 2017 , ... Benefits delivery trailblazer, ... mobile app and centralized benefits dashboard solving one of the top frustrations in ... locations. For the first time, employees can access up-to-date information and account balances ...
(Date:3/23/2017)... ... 23, 2017 , ... The Wound Certification Prep Course ... Holdings, LLC, today announced that RestorixHealth® has officially endorsed WCPC as ... interested in becoming Certified Wound Specialist Physicians (CWSP®). , This collaborative effort ...
(Date:3/23/2017)... ... March 23, 2017 , ... March 23, 2017 - Crawford ... easily reprint customer invoices, bills, statements and other correspondence when they have been ... to retrieve and print the documents and batch them for efficient handling. ...
Breaking Medicine News(10 mins):